Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abituzumab with Cetuximab and Irinotecan in mCRC (POSEIDON)
NCT01008475Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2009
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of abituzumab in colorectal cancer (metastatic) (mCRC), sponsored by Merck KGaA. Started Oct 2009; status: completed.
02
Drugs
abituzumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01008475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01008475.